A Single-Site, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Glucodynamic Effects of LY3192767 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2017
At a glance
- Drugs LY 3192767 (Primary) ; Insulin glargine; Insulin peglispro
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 30 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 21 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.